Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.52 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: pravastatin, rosuvastatin calcium, lovastatin +13 | 1.00 |
| trials ClinicalTrials.gov | 4 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 17 Parkinson's papers of 2,550 | 0.62 |
| pathways Reactome | 4 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 0200
Sealed predictions
- HMGCR in dopamine neurons, braak+0.05 (p 0.907) → +0.14 (p 0.716)receipt 0206
Swarm cases
receipt 0206: HMGCR in dopamine neurons, braak
- power
- full sample +0.00 (p 0.997, n 18), 95% CI -0.47 to +0.47. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.02 (p 0.935, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.06 (p 0.807, n 18). could be the mix.
- skeptic
- leave-one-out range -0.13 to +0.07, sign flips 7; without severely affected donors +0.00 (p 0.997, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for HMGCR in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts